MTBuVax™-Vaxils Tuberculosis Vaccine

VAXIL – Creating the ideal immunotherapy

Inducing a Broad

Response

Learn More

universally

Applicable

Learn More

Overcoming

Cancer Resistance

Learn More

Harnessing Potent

Immune Response

Learn More

Tumor

Specific

Learn More

Expression on

Cancer Stem Cells

Learn More

neo-antigen

acting

Learn More

First Ever SP-Specific

Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is ​its ImMucin™ ​lead immunotherapy product.